Australia is carefully awaiting the arrival of retatrutide, a innovative dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, this https://aadamebiu451982.wikinewspaper.com/4883577/novo_nordisk_s_retatrutide_australia_a_promising_hope_for_weight_management